Senate Approves $5.6 billion for Bioterror Provisions.  The government will guarantee purchase of these products, providing an incentive for private companies to invest the capital needed to develop them.

May 20, 2004


More than 2 billion people worldwide could be impacted by a pandemic. 160 million Americans will need to be vaccinated…

August 2009

Increasing Needs in the Immunocompromised Leukemia Patients. Amgen’s blockbuster brands Neulasta and Neupogen dominated the immuno-stimulant market in 2007, with sales of $3.5 billion and $1.4 bill respectively. Forecast sales for the immuno-stimulants market are estimated to reach $17.6 billion in 2013.

OfficialWire, London, July 30, 2009

“The ability of our innate immune systems to ramp up defenses against infections is very impressive. Manipulating this therapeutically has the potential to change the way cancer is treated, and fundamentally alter our vulnerability to epidemics and bioterror threats.” Dr. Burton Dickey

About Pulmotect

Pulmotect, Inc. is a Houston-based clinical stage biotechnology company, developing immunomodulatory products that boost the innate immune system to protect against a wide range of lung infections. Our co-founders are leaders in the emerging science of innate immunity in the lungs. Our technologies stimulate the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague).

Awards & Recognition

  • SouthEast Bio Investor Forum, Early Stage Shootout Winner
  • Rice Alliance Conference Awarded a “Most Promising Company” award
  • World’s Best Technology Showcase presentation
  • Top 5 award at the national NCET2 conference in Washington DC

[+] More Awards and Recognition